FDA Approves New Parkinson's Add-On Drug Xadago

Share this content:
FDA Approves New Parkinson's Add-On Drug Xadago
FDA Approves New Parkinson's Add-On Drug Xadago

WEDNESDAY, March 22, 2017 (HealthDay News) -- Xadago (safinamide) tablets have been approved by the U.S. Food and Drug Administration as an add-on drug to treat Parkinson's patients who take levodopa or carbidopa but experience "off" episodes.

Xadago's effectiveness was established in a clinical study of 645 patients who were taking levodopa but were still having "off" periods. Compared to patients who took a placebo, users of Xadago had fewer instances of Parkinson's symptoms.

Certain patients shouldn't take Xadago, including those with severe liver problems and those taking dextromethorphan, monoamine oxidase inhibitors, or certain antidepressants, the FDA said.

Xadago's most common side effects included involuntary movement, falls, nausea, and insomnia. More serious adverse reactions included worsening hypertension, falling asleep during daily activities, hallucinations, psychotic and/or compulsive behavior, fever, and confusion.

The FDA granted approval of Xadago to Newron Pharmaceuticals, based in Milan.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »